These include blastic plasmacytoid dendritic cell neoplasm (BPDCN), targeted through CD123; Waldenströms macroglobulinemia (WM), addressed through the NKG2D ligand (NKG2DL); and myelodysplastic syndromes (MDS), which are targeted using CD70. Here, CD70 is linked to myelodysplastic syndrome.